Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 13/20 | 0.79 |
| ▸ | AKT1 | P31749 | 11/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.79 |
| ▸ | GSK3B | P49841 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491469 | 0.90 | AKT2 (0.64) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL1001031 | 0.88 | AKT2 (1.00) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL13510877 | 0.87 | AKT1 (0.73) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL3491359 | 0.85 | AKT1 (0.60) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL13343919 | 0.85 | AKT1 (0.66) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL3491738 | 0.84 | AKT1 (0.68) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL3493479 | 0.84 | AKT2 (0.63) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL387982 | 0.83 | AKT1 (1.00) | AKT2AKT1ROCK2KCNH2AKT3 | |
| SCHEMBL387983 | 0.83 | AKT1 (1.00) | AKT2AKT1ROCK2KCNH2AKT3 | |
| SCHEMBL391464 | 0.83 | AKT1 (1.00) | AKT2AKT1ROCK2KCNH2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | AKT2 71/4885AKT1 92/4885CYP2C9 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.